Fox Run Management, L.L.C. Bei Gene, Ltd. Transaction History

Fox Run Management, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$158.67 - $201.58 $357,483 - $454,159	2,253 New	2,253 $406,000
Q2 2020 Jul 31, 2020	SELL	$123.9 - $195.41 $217,196 - $342,553	-1,753 Closed	0 $0
Q1 2020 May 08, 2020	BUY	$121.84 - $173.19 $213,585 - $303,602	1,753 New	1,753 $216,000
Q3 2018 Oct 05, 2018	SELL	$152.62 - $189.66 $748,143 - $929,713	-4,902 Closed	0 $0
Q2 2018 Jul 17, 2018	BUY	$152.5 - $216.77 $747,555 - $1.06 Million	4,902 New	4,902 $754,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.